Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Chronic Myeloid Leukemia
CHRONIC MYELOID LEUKEMIA ADVISOR
FEATURED CONTENT
-
-
Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML
Although patients with CML may not be eligible for TKI discontinuation based on transcript alone, the type of transcript seen may have some implications for loss of treatment remission. -
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%… -
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services. -
Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic imatinib at a higher frequency compared with those given brand-name products.
VIDEO SERIES
Ponatinib for CML
Progress in the CML Landscape
Treatment Options
Sequencing Treatment
Choosing the Appropriate TKI
Monitoring Treatment Response
Monitoring Adherence
Switching Therapies
Discontinuing Treatment
Known Factors in TKI Resistance
Managing Adverse Events
Allogeneic Stem Cell Transplant
CML: On the Horizon
The Future of CML Treatment
CHRONIC MYELOID LEUKEMIA NEWS
Second-Generation TKIs in Advanced CML: 7-Year Survival Rates
Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries
Prototype Intervention Increased Adherence to TKIs in CML
Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
Want to read more?
Please login or register first to view this content.
Next post in Chronic Myeloid Leukemia
